Research programme: serine protease inhibitor - Syntara Limited
Latest Information Update: 13 Dec 2023
At a glance
- Originator Pharmaxis
- Developer Syntara Limited
- Class Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action Serine protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation; Skin disorders